Physician profile
Kaoru Harada
NPI 1215383864
$1,829.12
in general payments reported to CMS, 2019-2025
12 companies · $26.37 in 2025
The $26.37 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $58.78 · 2021: $1,125 · 2022: $145 · 2023: $229 · 2024: $135 · 2025: $26.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allerderm Laboratories | $1,000.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $169.44 | 2023-2024 | |
| Novo Nordisk INC | $125.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $122.20 | 2022 | |
| Optinose US, INC. | $111.10 | 2019 | |
| Glaxosmithkline, LLC. | $89.73 | 2024-2025 | Nucala |
| Alk-Abello, INC | $58.78 | 2020 | |
| Genentech USA, INC. | $52.74 | 2023 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $44.24 | 2023 | Cuvitru |
| Amgen INC. | $22.41 | 2022 | |
| Pfizer INC. | $17.99 | 2023 | |
| Genzyme Corporation | $15.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaoru Harada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.